T10643 |
C-Fms-IN-1
|
885703-64-0
|
98%
|
|
c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).
|
T10648 |
C-Fms-IN-9
|
1628574-50-4
|
98%
|
|
c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1 (Example 7). It inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT (IC50s: <0.01 μM and ...
|
T10649 |
C-Fms-IN-3
|
885704-21-2
|
98%
|
|
c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.
|
T6104 |
Cerdulatinib hydrochloride
|
1369761-01-2
|
98%
|
|
Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and S...
|
T1925 |
PLX647
|
873786-09-5
|
98%
|
|
PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).
|
T61589 |
C-Fms-IN-13
|
885704-58-5
|
98%
|
|
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.
|
T12505 |
PLX5622 hemifumarate
|
T12505
|
98%
|
|
PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor with an IC 50 of 0.016 μM and Ki of 5.9 nM. PLX5622 hemifumarate all...
|
T11734 |
K-80003
|
1292821-90-9
|
98%
|
|
K-80003 is a potent inhibitor of cancer cell growth and tRXRα-dependent Akt activation.
|
T10645 |
C-Fms-IN-6
|
1628574-81-1
|
98%
|
|
c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: > 1 μM).
|
T35570 |
Chiauranib
|
1256349-48-0
|
96.25%
|
|
Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related k...
|
T10775 |
C-Fms-IN-2
|
791587-67-2
|
97.34%
|
|
c-Fms-IN-2 is an inhibitor of c-FMS kinase (IC50 = 24 nM).
|
T2116 |
AEE788
|
497839-62-0
|
98%
|
|
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
T6028 |
PF 477736
|
952021-60-2
|
98.34%
|
|
PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
|
T10894 |
CSF1R-IN-1
|
2095849-04-8
|
98.57%
|
|
CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.
|
T10652 |
Vimseltinib
|
1628606-05-2
|
98.98%
|
|
DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).
|
T2514 |
Linifanib
|
796967-16-3
|
99.29%
|
|
Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: ...
|
T4315 |
Ki20227
|
623142-96-1
|
99.37%
|
|
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451...
|
T4376 |
Nampt-IN-1
|
1698878-14-6
|
99.4%
|
|
Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.
|
T2659 |
GW2580
|
870483-87-7
|
99.48%
|
|
GW2580 is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
|
T2115 |
Pexidartinib
|
1029044-16-3
|
99.66%
|
|
Pexidartinib is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic a...
|